An eruption of basal cell carcinoma after ibrutinib

Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been report...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings (Baylor University. Medical Center) 2024, Vol.37 (2), p.334-335
Main Authors: Pan, Sharon, Housewright, Chad
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 335
container_issue 2
container_start_page 334
container_title Proceedings (Baylor University. Medical Center)
container_volume 37
creator Pan, Sharon
Housewright, Chad
description Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been reports of a significantly increased incidence. Here, we present a patient with no dermatologic history who subsequently developed nearly 30 incidents of basal cell carcinoma after starting ibrutinib, leading to discontinuation of the therapy.
doi_str_mv 10.1080/08998280.2023.2288482
format report
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2926073950</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2926073950</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_29260739503</originalsourceid><addsrcrecordid>eNqVjEsKwjAURTNQsH6WIGTopPXlpdpkKKK4AOclKSlE2qTms38tuAEn98K5h0vInkHFQMARhJQCBVQIyCtEIWqBC1LMvJyHFVnH-AKoGWdNQfjFURPylKx31PdUq6gG2pnhGyp01vlRUdUnE6jVISfrrN6SZa-GaHa_3pDD_fa8Psop-Hc2MbWjjfOFcsbn2KLEMzRcnoD_oX4AaTg9gQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2926073950</pqid></control><display><type>report</type><title>An eruption of basal cell carcinoma after ibrutinib</title><source>PubMed (Medline)</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Pan, Sharon ; Housewright, Chad</creator><creatorcontrib>Pan, Sharon ; Housewright, Chad</creatorcontrib><description>Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been reports of a significantly increased incidence. Here, we present a patient with no dermatologic history who subsequently developed nearly 30 incidents of basal cell carcinoma after starting ibrutinib, leading to discontinuation of the therapy.</description><identifier>ISSN: 0899-8280</identifier><identifier>DOI: 10.1080/08998280.2023.2288482</identifier><language>eng</language><ispartof>Proceedings (Baylor University. Medical Center), 2024, Vol.37 (2), p.334-335</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784,4490,27925</link.rule.ids></links><search><creatorcontrib>Pan, Sharon</creatorcontrib><creatorcontrib>Housewright, Chad</creatorcontrib><title>An eruption of basal cell carcinoma after ibrutinib</title><title>Proceedings (Baylor University. Medical Center)</title><description>Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been reports of a significantly increased incidence. Here, we present a patient with no dermatologic history who subsequently developed nearly 30 incidents of basal cell carcinoma after starting ibrutinib, leading to discontinuation of the therapy.</description><issn>0899-8280</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2024</creationdate><recordtype>report</recordtype><recordid>eNqVjEsKwjAURTNQsH6WIGTopPXlpdpkKKK4AOclKSlE2qTms38tuAEn98K5h0vInkHFQMARhJQCBVQIyCtEIWqBC1LMvJyHFVnH-AKoGWdNQfjFURPylKx31PdUq6gG2pnhGyp01vlRUdUnE6jVISfrrN6SZa-GaHa_3pDD_fa8Psop-Hc2MbWjjfOFcsbn2KLEMzRcnoD_oX4AaTg9gQ</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Pan, Sharon</creator><creator>Housewright, Chad</creator><scope>7X8</scope></search><sort><creationdate>20240101</creationdate><title>An eruption of basal cell carcinoma after ibrutinib</title><author>Pan, Sharon ; Housewright, Chad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_29260739503</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Pan, Sharon</creatorcontrib><creatorcontrib>Housewright, Chad</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Sharon</au><au>Housewright, Chad</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>An eruption of basal cell carcinoma after ibrutinib</atitle><jtitle>Proceedings (Baylor University. Medical Center)</jtitle><date>2024-01-01</date><risdate>2024</risdate><volume>37</volume><issue>2</issue><spage>334</spage><epage>335</epage><pages>334-335</pages><issn>0899-8280</issn><abstract>Ibrutinib is a therapy targeting tyrosine kinase that has been used for various hematologic malignancies. It is associated with a variety of adverse effects, several of which are dermatologic. While there are few discussions of basal cell carcinoma as an adverse event, there have not yet been reports of a significantly increased incidence. Here, we present a patient with no dermatologic history who subsequently developed nearly 30 incidents of basal cell carcinoma after starting ibrutinib, leading to discontinuation of the therapy.</abstract><doi>10.1080/08998280.2023.2288482</doi></addata></record>
fulltext fulltext
identifier ISSN: 0899-8280
ispartof Proceedings (Baylor University. Medical Center), 2024, Vol.37 (2), p.334-335
issn 0899-8280
language eng
recordid cdi_proquest_miscellaneous_2926073950
source PubMed (Medline); Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
title An eruption of basal cell carcinoma after ibrutinib
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T10%3A17%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=An%20eruption%20of%20basal%20cell%20carcinoma%20after%20ibrutinib&rft.jtitle=Proceedings%20(Baylor%20University.%20Medical%20Center)&rft.au=Pan,%20Sharon&rft.date=2024-01-01&rft.volume=37&rft.issue=2&rft.spage=334&rft.epage=335&rft.pages=334-335&rft.issn=0899-8280&rft_id=info:doi/10.1080/08998280.2023.2288482&rft_dat=%3Cproquest%3E2926073950%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_29260739503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2926073950&rft_id=info:pmid/&rfr_iscdi=true